Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) has a cash flow conversion efficiency ratio of -0.037x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.51 Million) by net assets ($123.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Eupraxia Pharmaceuticals Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Eupraxia Pharmaceuticals Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read EPRX liabilities breakdown for a breakdown of total debt and financial obligations.
Eupraxia Pharmaceuticals Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eupraxia Pharmaceuticals Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hyundai Motor Securities Co. Ltd.
KO:001500
|
-0.045x |
|
Servcorp Ltd
AU:SRV
|
0.361x |
|
Shaanxi Meibang Pharmaceutical Group Co Ltd
SHG:605033
|
0.246x |
|
DINGDONG CAYMAN 2ADR/3 A
F:945
|
N/A |
|
Longxing Chemical Stock Co Ltd
SHE:002442
|
-0.009x |
|
Varex Imaging Corp
NASDAQ:VREX
|
-0.033x |
|
ProCredit Holding AG & Co KGaA
XETRA:PCZ
|
-0.342x |
|
Unipar Carbocloro S.A
SA:UNIP3
|
0.097x |
Annual Cash Flow Conversion Efficiency for Eupraxia Pharmaceuticals Inc. Common Stock (2017–2024)
The table below shows the annual cash flow conversion efficiency of Eupraxia Pharmaceuticals Inc. Common Stock from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Eupraxia Pharmaceuticals Inc. Common Sto (EPRX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $31.84 Million | $-29.99 Million | -0.942x | +95.95% |
| 2023-12-31 | $892.33K | $-20.75 Million | -23.252x | -1476.36% |
| 2022-12-31 | $9.76 Million | $-14.40 Million | -1.475x | -143.62% |
| 2021-12-31 | $19.12 Million | $-11.58 Million | -0.605x | -3348.52% |
| 2020-12-31 | $-21.66 Million | $-403.78K | 0.019x | -93.46% |
| 2019-12-31 | $-18.13 Million | $-5.17 Million | 0.285x | -60.80% |
| 2018-12-31 | $-11.44 Million | $-8.32 Million | 0.728x | +170.13% |
| 2017-12-31 | $5.11 Million | $-5.30 Million | -1.038x | -- |
About Eupraxia Pharmaceuticals Inc. Common Stock
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unm… Read more